In the third and final part of this Insider Insights series, CLINUVEL’s Chair Willem Blijdorp and Professor Kitty Koelemeijer discuss navigating contemporary challenges within a public company...
In this second of three Insider Insights, CLINUVEL’s Chair Willem Blijdorp and Professor Kitty Koelemeijer explore the products, people and social purpose of the ASX-listed Group (CUV).
CLINUVEL has today announced that its drug afamelanotide was well tolerated by the first three arterial ischaemic stroke (AIS) patients enrolled in a world first clinical trial (CUV801). Watch our new video explaining the pathology and treatment of stroke.
Those of us working from offices, or our own homes, aren’t expecting danger pay.  However, what about those who have jobs that heighten the risk of getting skin...
In an investor and analyst webinar hosted by CLINUVEL, Mr Malcolm Bull, Head of Investor Relations, is joined by Mr Darren Keamy, Chief Financial Officer, and Dr Philippe Wolgen, Managing Director, in discussing the financial results for the year ended 30 June 2022 and the Company’s plans for FY2023 and beyond.
In a webcast addressed to shareholders, CLINUVEL’s Managing Director, Dr Philippe Wolgen, covers CLINUVEL’s market position, financial management and the Group’s unfolding growth and expansion strategy.
CLINUVEL’s Chief Financial Officer, Darren Keamy, and Director of Global Operations, Lachlan Hay, discuss the financial results for the half year ended 31 December 2021, the Company’s multi-pronged growth and expansion strategy and the activities of the Pharmaceuticals and Healthcare Solutions Divisions.